Simon Rule

11.6k total citations · 1 hit paper
155 papers, 3.4k citations indexed

About

Simon Rule is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Simon Rule has authored 155 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Pathology and Forensic Medicine, 98 papers in Genetics and 62 papers in Oncology. Recurrent topics in Simon Rule's work include Lymphoma Diagnosis and Treatment (112 papers), Chronic Lymphocytic Leukemia Research (96 papers) and Viral-associated cancers and disorders (40 papers). Simon Rule is often cited by papers focused on Lymphoma Diagnosis and Treatment (112 papers), Chronic Lymphocytic Leukemia Research (96 papers) and Viral-associated cancers and disorders (40 papers). Simon Rule collaborates with scholars based in United Kingdom, United States and France. Simon Rule's co-authors include M. Dreyling, Marco Ladetto, Steven Le Gouill, Mats Jerkeman, Jan Walewski, Ofer Shpilberg, Olivier Hermine, Elı́as Campo, Michele Ghielmini and Gilles Salles and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Simon Rule

150 papers receiving 3.4k citations

Hit Papers

Newly diagnosed and relapsed mantle cell lymphoma: ESMO C... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 412 citations M. Dreyling, Elı́as Campo et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simon Rule United Kingdom 30 2.4k 1.7k 1.6k 593 519 155 3.4k
John Sweetenham United States 34 2.8k 1.1× 2.0k 1.2× 1.5k 1.0× 809 1.4× 785 1.5× 143 4.6k
Judith Trotman Australia 27 2.7k 1.1× 1.3k 0.8× 1.3k 0.8× 464 0.8× 421 0.8× 159 3.6k
Paul A. Hamlin United States 33 2.9k 1.2× 2.0k 1.2× 925 0.6× 372 0.6× 587 1.1× 155 4.0k
Mathias Rummel Germany 29 3.1k 1.3× 2.1k 1.2× 2.2k 1.4× 1.6k 2.7× 530 1.0× 128 5.0k
Graham P. Collins United Kingdom 25 1.6k 0.7× 1.6k 1.0× 686 0.4× 292 0.5× 584 1.1× 160 2.7k
Andreas Lohri Switzerland 24 2.1k 0.9× 1.5k 0.9× 735 0.5× 277 0.5× 333 0.6× 69 2.8k
William R. Macon United States 39 3.6k 1.5× 2.4k 1.4× 1.3k 0.8× 268 0.5× 921 1.8× 139 4.9k
David Westerman Australia 27 1.4k 0.6× 776 0.5× 1.4k 0.9× 732 1.2× 545 1.1× 125 2.8k
Paolo G. Gobbi Italy 29 1.6k 0.6× 905 0.5× 686 0.4× 435 0.7× 281 0.5× 86 2.6k
Tak Takvorian United States 27 1.5k 0.6× 1.1k 0.7× 899 0.6× 957 1.6× 534 1.0× 58 2.9k

Countries citing papers authored by Simon Rule

Since Specialization
Citations

This map shows the geographic impact of Simon Rule's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Rule with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Rule more than expected).

Fields of papers citing papers by Simon Rule

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Rule. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Rule. The network helps show where Simon Rule may publish in the future.

Co-authorship network of co-authors of Simon Rule

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Rule. A scholar is included among the top collaborators of Simon Rule based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Rule. Simon Rule is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brown, Jennifer R., et al.. (2024). COVID-19 vaccination during therapy in relation to COVID-19 death in CLL. Blood Advances. 8(20). 5262–5265. 1 indexed citations
2.
Sharman, Jeff P., et al.. (2023). Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib from 5 Prospective Clinical Trials. Blood. 142(Supplement 1). 4643–4643. 1 indexed citations
3.
Tam, Constantine S., Stephen Opat, David Simpson, et al.. (2021). Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances. 5(12). 2577–2585. 63 indexed citations
4.
Dreyling, M., Michele Ghielmini, Simon Rule, et al.. (2020). Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 32(3). 298–308. 132 indexed citations
5.
Gouill, Steven Le, Franck Morschhauser, David Chiron, et al.. (2020). Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 137(7). 877–887. 75 indexed citations
6.
Danilov, Alexey V., Charles Herbaux, Harriet S. Walter, et al.. (2020). Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(12). 2810–2818. 47 indexed citations
7.
Morschhauser, Franck, Martin J.S. Dyer, Harriet S. Walter, et al.. (2020). Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia. 35(7). 2108–2113. 13 indexed citations
8.
Phillips, Elizabeth H., Catherine Burton, Amy A. Kirkwood, et al.. (2020). Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial. SHILAP Revista de lepidopterología. 1(1). 133–141. 6 indexed citations
9.
Rule, Simon, Martin Dreyling, André Goy, et al.. (2019). Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. Blood. 134(Supplement_1). 1538–1538. 16 indexed citations
10.
McCulloch, Rory, Carlo Visco, Rebecca Frewin, et al.. (2019). R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy. Blood. 134(Supplement_1). 3989–3989. 4 indexed citations
11.
McCulloch, Rory, et al.. (2018). Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma. British Journal of Haematology. 185(5). 1002–1004. 1 indexed citations
12.
13.
Jurczak, Wojciech, Simon Rule, William Townsend, et al.. (2017). First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes. Blood. 130. 2778–2778. 3 indexed citations
14.
Arcaini, Luca, Thierry Lamy, Jan Walewski, et al.. (2017). Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology. 180(2). 224–235. 9 indexed citations
15.
Rule, Simon, Martin Dreyling, André Goy, et al.. (2017). Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis. Blood. 130. 151–151. 4 indexed citations
16.
17.
Trněný, Marek, Jan Walewski, David Belada, et al.. (2015). IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY. Haematologica. 100(4). 2 indexed citations
18.
Furtado, Michelle, et al.. (2012). Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma. British Journal of Haematology. 160(1). 63–69. 7 indexed citations
19.
20.
Rule, Simon, et al.. (1994). Serum vitamin B12 and transcobalamin levels in early HIV disease. American Journal of Hematology. 47(3). 167–171. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Sweetenham Breakdown of academic impact, for papers by Judith Trotman Breakdown of academic impact, for papers by Paul A. Hamlin Breakdown of academic impact, for papers by Mathias Rummel Breakdown of academic impact, for papers by Graham P. Collins Breakdown of academic impact, for papers by Andreas Lohri Breakdown of academic impact, for papers by William R. Macon Breakdown of academic impact, for papers by David Westerman Breakdown of academic impact, for papers by Paolo G. Gobbi Breakdown of academic impact, for papers by Tak Takvorian
Rankless by CCL
2026